Amendment to the claims:

1. (currently amended) A method of treating a ~~disease chosen from the group consisting of psoriasis, ulcers, gastroesophageal reflux,~~ condition chosen from ulcers, Zollinger-Ellison Syndrome, and ~~conditions caused by or contributed to by gastric hypersecretion,~~ gastroesophageal reflux disease, said method comprising administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

2. (original) A method according to claim 1 of treating ulcers which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

3. (original) A method according to claim 1 of treating gastroesophageal reflux disease which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

4. (canceled)

5. (currently amended) The method according to claim [[4]] 1 wherein said condition is Zollinger-Ellison Syndrome.

6. (canceled)

7. (original) The method of claim 1 wherein racemic hydroxylansoprazole is administered.

8. (original) The method of claim 7 wherein the amount of racemic hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1500 mg per day.

9. (original) The method of claim 7 wherein racemic hydroxylansoprazole is administered orally.

10. (original) The method of claim 1 wherein optically pure (+)-hydroxylansoprazole is administered.

11. (original) The method of claim 10 wherein the amount of (+)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.

12. (original) The method of claim 10 wherein optically pure (+)-hydroxylansoprazole is administered orally.

13. (original) The method of claim 1 wherein optically pure (-)-hydroxylansoprazole is administered.

14. (original) The method of claim 13 wherein the amount of (-)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.

15. (original) The method of claim 13 wherein optically pure (-)-hydroxylansoprazole is administered orally.